Home / Companies / Butterfly Network
BFLY · Updated
Butterfly Network
In the Bet The Decade Portfolio
Butterfly Network makes handheld point-of-care ultrasound devices built on its Ultrasound-on-Chip semiconductor platform, paired with cloud-connected software. In its latest fiscal year (ended 31 December 2025) it reported revenue of $97.6 million and a net loss of $77.1 million, according to its 10-K filed on 27 February 2026. Bet The Decade has covered Butterfly Network in 1 episode, most recently “What Is Butterfly Network Really Worth Now That AI Wants Its Chip?” (9 November 2026).
Business description summarized from 10-K (Item 1, Business), filed 2026-02-27. Figures: SEC EDGAR, retrieved 16 November 2026.
Not financial advice.
Portfolio weight: 0.7% · as of 13 Nov 2026 close · Bet The Decade Portfolio →
Next results: date not announced by the company yet (TBA). Earnings calendar →
Watch: What Is Butterfly Network Really Worth Now That AI Wants Its Chip?
Watch ▶Bet The Decade on YouTube, 9 November 2026. The video loads only after you press play. Transcript, chapters and sources →
Thesis & risks
From our episodes
Thesis: “My bottom line: the chip was not the mistake. The chip is the reason AI companies are now paying Butterfly.” From What Is Butterfly Network Really Worth Now That AI Wants Its Chip? (9 November 2026), chapter at 0:00.
Opinion from the video, quoted from the transcript. Price targets and valuation scenarios are never reproduced.
Risks the company lists
- We have a limited history of generating revenue from sales of our products, and we have incurred significant losses since inception. We anticipate that we will continue to incur losses for at least the next several years as we…
- Our success depends upon market acceptance of our products and services, our ability to develop and commercialize existing and new products and services and generate revenues, and our ability to identify new markets for our…
- Medical device development is costly and involves continual technological change, which may render our current or future medical devices obsolete.
- We are dependent upon the success of our sales and customer acquisition and retention strategies.
Quoted (shortened) from the risk factor summary of its 10-K filed 27 February 2026. The full list is longer; read Item 1A (Risk Factors).
Key data
| Field | Value | Source |
|---|---|---|
| Legal name (SEC) | Butterfly Network, Inc. | SEC EDGAR, CIK 0001804176 |
| Ticker · exchange | BFLY · NYSE | SEC submissions data |
| Industry (SEC SIC) | X-Ray Apparatus & Tubes & Related Irradiation Apparatus | SEC EDGAR company profile |
| Incorporated in | DE | SEC EDGAR company profile |
| Revenue, latest fiscal year | $97.6 million · 1 January 2025 to 31 December 2025 | 10-K filed 2026-02-27 · XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax = 97,610,000 USD |
| Net income (loss), latest fiscal year | -$77.1 million · 1 January 2025 to 31 December 2025 | 10-K filed 2026-02-27 · XBRL us-gaap:NetIncomeLoss = -77,064,000 USD |
| Revenue, latest reported quarter | $32.6 million · 1 July 2026 to 30 September 2026 | 10-Q filed 2026-10-29 · XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax = 32,598,000 USD |
| Cash and cash equivalents | $122.3 million · as of 30 September 2026 | 10-Q filed 2026-10-29 · XBRL us-gaap:CashAndCashEquivalentsAtCarryingValue = 122,301,000 USD |
| Latest results release | 8-K (Item 2.02) filed 29 October 2026 | SEC filing index |
| Latest annual report | 10-K for period ending 31 December 2025 | Filed 2026-02-27 |
| Latest quarterly report (10-Q) | 10-Q for period ending 30 September 2026 | Filed 2026-10-29 |
Compare with Tempus AI and Hims & Hers →10 years forward calculator →
Revenue and share count
Source: SEC XBRL company facts from the 10-Q and 10-K filings, retrieved 16 November 2026. * Fourth quarter = fiscal-year total in the 10-K minus the three reported quarters (the 10-K does not report Q4 separately).
Data and sources
| Period end | Value | Source |
|---|---|---|
| 31 December 2024 * | $22.4M · 22,352,000 | 10-K filed 2026-02-27 · us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · derived |
| 31 March 2025 | $21.2M · 21,225,000 | 10-Q filed 2026-04-30 · us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| 30 June 2025 | $23.4M · 23,383,000 | 10-Q filed 2026-07-30 · us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| 30 September 2025 | $21.5M · 21,489,000 | 10-Q filed 2026-10-29 · us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| 31 December 2025 * | $31.5M · 31,513,000 | 10-K filed 2026-02-27 · us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · derived |
| 31 March 2026 | $26.5M · 26,530,000 | 10-Q filed 2026-04-30 · us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| 30 June 2026 | $32.6M · 32,612,000 | 10-Q filed 2026-07-30 · us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| 30 September 2026 | $32.6M · 32,598,000 | 10-Q filed 2026-10-29 · us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
Recent SEC filings
| Filed | Form | What it is |
|---|---|---|
| S-3ASR | Automatic shelf registration | |
| 10-Q | Quarterly report | |
| 8-K | Current report: Results of operations | |
| 8-K | Current report: Director or officer change | |
| 8-K | Current report: Director or officer change | |
| 10-Q | Quarterly report | |
| 8-K | Current report: Results of operations | |
| 8-K | Current report: Shareholder vote results |
SEC EDGAR
- All filingsSEC EDGAR · CIK 0001804176sec.gov
- Annual reports10-K filingssec.gov
- Quarterly / current10-Q filingssec.gov
- XBRL dataCompany facts (JSON)data.sec.gov
FAQ
What does Butterfly Network do?
Butterfly Network makes handheld point-of-care ultrasound devices built on its Ultrasound-on-Chip semiconductor platform, paired with cloud-connected software.
Sources: sec.gov/Archives/edgar/data/1804176/000180417626000009/bfly-20251231.htm
Where can I read Butterfly Network's official filings?
Butterfly Network files with the US Securities and Exchange Commission under CIK 0001804176. Its annual and quarterly reports are on SEC EDGAR.
Sources: sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001804176
When does Butterfly Network report results next?
Butterfly Network has not announced its next results date yet (TBA). This page shows a date only after the company announces it.
Which Bet The Decade episodes cover Butterfly Network?
Bet The Decade has covered Butterfly Network in 1 episode. The most recent is “What Is Butterfly Network Really Worth Now That AI Wants Its Chip?” (9 November 2026); its page has the video, chapters, the transcript and the sources.
Sources: betthedecade.com/episodes/what-is-butterfly-network-really-worth-now-that-ai-wants-its-chip/ · betthedecade.com/episodes/
What risks does Butterfly Network list in its filings?
In its 10-K filed 27 February 2026, Butterfly Network lists risks including: We have a limited history of generating revenue from sales of our products, and we have incurred significant losses since inception. We anticipate that we will continue to incur…; Our success depends upon market acceptance of our products and services, our ability to develop and commercialize existing and new products and services and generate revenues, and…; Medical device development is costly and involves continual technological change, which may render our current or future medical devices obsolete. The full list is in Item 1A (Risk Factors).
Sources: sec.gov/Archives/edgar/data/1804176/000180417626000009/bfly-20251231.htm
Is handheld ultrasound “AI diagnosis”?
Company markets AI-assisted guidance features; diagnosis remains a clinician responsibility. Not medical advice.
Sources: butterflynetwork.com/
What did Butterfly Network report for Q3 2026?
Butterfly Network reported Q3 2026 revenue of $32.6 million (+52% year over year) and raised FY2026 revenue guidance to $123–126 million; Q4 guidance is $31–34 million.
Sources: ir.butterflynetwork.com/News/press-releases/news-details/2026/Butterfly-Network- · sec.gov/Archives/edgar/data/1804176/000180417626000040/bfly-20260930.htm
Episodes
Related companies
Tempus AI (TEM) · Hims & Hers (HIMS) · 10x Genomics (TXG) · Nautilus Biotechnology (NAUT) · Recursion (RXRX) · ImmunityBio (IBRX) · CRISPR Therapeutics (CRSP)
Themes: Biotech
Guides and tools
Tools: 10-Year Calculator · Compare companies · Portfolio Growth Model
Page status: Complete. Last updated 16 November 2026.